Maria Vittoria Alesi

Dr. Maria Vittoria Alesi

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2025 in Human Reproduction Open
Verified
Journal Article
Open access
EPEmma Bonetti Palermo
Emma Bonetti Palermo
EFELEONORA LA FERA
ELEONORA LA FERA
MAMaria Vittoria Alesi
Maria Vittoria Alesi
SILVIA D'IPPOLITOSILVIA D'IPPOLITO
SILVIA D'IPPOLITO
ALAntonio Lanzone
Antonio Lanzone
UCUrsula Catena
Ursula Catena
Conservative management of caesarean scar pregnancy: tissue removal device hysteroscopic treatment after uterine artery embolisation - Facts, Views and Vision in ObGyn

18 March 2026 in Human Reproduction Open
Verified
Journal Article
Open access
PDF file
MIManuel Maria Ianieri
Manuel Maria Ianieri
MAMaria Vittoria Alesi
Maria Vittoria Alesi
ACAntonella Carcagnì
Antonella Carcagnì
MFMatteo Figà
Matteo Figà
FCFederica Campolo
Federica Campolo
AFANNA FAGOTTI
ANNA FAGOTTI
Surgical outcomes according to the degree of parametrial dissection with hysterectomy for deep endometriosis - Facts, Views and Vision in ObGyn

13 August 2026 in Placenta
Verified
Journal Article
Open access
ETEleonora Torcia
Eleonora Torcia
GBGiulia Bonanni
Giulia Bonanni
FFFrancesca Felici
Francesca Felici
MAMaria Vittoria Alesi
Maria Vittoria Alesi
RCRossana Cottone
Rossana Cottone
EBElisa Bevilacqua
Elisa Bevilacqua

31 May 2025 in Diagnostics
Verified
Journal Article
Open access
PDF file
ETEleonora Torcia
Eleonora Torcia
AFAlessandra Familiari¹
Alessandra Familiari¹
EPElvira Passananti
Elvira Passananti
MAMaria Vittoria Alesi
Maria Vittoria Alesi
GMGiulia di Marco
Giulia di Marco
EBElisa Bevilacqua
Elisa Bevilacqua
In 2024, Europe experienced a significant upsurge in cases of Parvovirus B19 (B19V), the etiological agent of erythema infectiosum, also known as fifth disease. The prevalence of B19V in pregnant women, a particularly vulnerable population, holds critical clinical significance. Typically, B19V follows a well-documented seasonal pattern, with annual epidemics peaking in the spring and larger outbreaks occurring approximately every four years. B19V exhibits a tropism for erythroid precursor cells, potentially resulting in fetal anemia and, in the most severe scenarios, intrauterine demise. Severe in utero infections necessitate intrauterine erythrocyte transfusion (IUT), a highly specialized and technically demanding procedure that is exclusively performed in tertiary-level prenatal care units. This study delineates how the notable increase in B19V infections is also reflected in our prenatal diagnosis unit at Fondazione Policlinico Agostino Gemelli (FPG) IRCCS, Rome, Italy. According to our case series, since 2018, B19V has been identified as the second most common cause of fetal anemia during the study period (29%, 6 patients), yet it accounted for the majority of IUT procedures performed in 2024 (16 out of 19 cases, 84.2%). Given the rising incidence of severe intrauterine infections in recent epidemic cycles, healthcare professionals should maintain a high index of suspicion regarding the clinical manifestations of maternal B19V infection and its potential obstetric complications. Further research is imperative to evaluate the cost-effectiveness of routine screening for B19V immunity in pregnant women and to investigate the long-term neurodevelopmental and clinical outcomes of neonates affected by intrauterine B19V infection.